MX2021014526A - Metodos no terapeuticos para mantener un peso corporal saludable o perder peso corporal. - Google Patents

Metodos no terapeuticos para mantener un peso corporal saludable o perder peso corporal.

Info

Publication number
MX2021014526A
MX2021014526A MX2021014526A MX2021014526A MX2021014526A MX 2021014526 A MX2021014526 A MX 2021014526A MX 2021014526 A MX2021014526 A MX 2021014526A MX 2021014526 A MX2021014526 A MX 2021014526A MX 2021014526 A MX2021014526 A MX 2021014526A
Authority
MX
Mexico
Prior art keywords
body weight
maintaining
losing
therapeutic methods
healthy
Prior art date
Application number
MX2021014526A
Other languages
English (en)
Inventor
Ellen Elisabeth Blaak
Emanuel Enzo Canfora
Arjen Nauta
Original Assignee
Frieslandcampina Nederland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frieslandcampina Nederland Bv filed Critical Frieslandcampina Nederland Bv
Publication of MX2021014526A publication Critical patent/MX2021014526A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pediatric Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a un método no terapéutico para mantener un peso corporal saludable o perder peso corporal en un sujeto, en el que el método no terapéutico comprende la etapa de administrar 2'-fucosil-lactosa y almidón resistente y en el que el sujeto tiene un peso delgado.
MX2021014526A 2019-05-29 2020-05-26 Metodos no terapeuticos para mantener un peso corporal saludable o perder peso corporal. MX2021014526A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19177345 2019-05-29
EP19180567 2019-06-17
PCT/EP2020/064505 WO2020239726A1 (en) 2019-05-29 2020-05-26 Non-therapeutic methods for maintaining a healthy body weight or losing body weight

Publications (1)

Publication Number Publication Date
MX2021014526A true MX2021014526A (es) 2022-03-17

Family

ID=70779786

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014526A MX2021014526A (es) 2019-05-29 2020-05-26 Metodos no terapeuticos para mantener un peso corporal saludable o perder peso corporal.

Country Status (8)

Country Link
US (1) US20230189864A1 (es)
EP (1) EP3976052A1 (es)
CN (1) CN113905742A (es)
AU (1) AU2020281701A1 (es)
MX (1) MX2021014526A (es)
SG (1) SG11202112339TA (es)
TW (1) TW202103580A (es)
WO (1) WO2020239726A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268367A (en) * 1991-12-30 1993-12-07 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Composition and method for lowering blood level of LDL-cholesterol
US8197872B2 (en) 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
US9453230B2 (en) 2011-02-16 2016-09-27 Glycosyn LLC Biosynthesis of human milk oligosaccharides in engineered bacteria
WO2016091265A1 (en) * 2014-12-08 2016-06-16 Glycom A/S Synthetic composition for treating metabolic disorders
DK3349763T3 (en) * 2015-09-14 2021-11-15 Glycom As Composition for use in microbiota modulation
EP3407897A1 (en) * 2016-01-26 2018-12-05 Nestec S.A. Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat a health disorder by increasing glp-1 secretion
WO2018207110A1 (en) * 2017-05-09 2018-11-15 Glycom A/S Synthetic composition for microbiota modulation

Also Published As

Publication number Publication date
WO2020239726A1 (en) 2020-12-03
SG11202112339TA (en) 2021-12-30
EP3976052A1 (en) 2022-04-06
TW202103580A (zh) 2021-02-01
US20230189864A1 (en) 2023-06-22
AU2020281701A1 (en) 2021-11-25
CN113905742A (zh) 2022-01-07

Similar Documents

Publication Publication Date Title
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
UA85055C2 (ru) Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
PH12020500555A1 (en) Esketamine for the treatment of depression
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MX2020010369A (es) Particulas implantables y metodos relacionados.
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
MX2021008131A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
MX2023010063A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2022014034A (es) Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta.
MX2010000368A (es) Metodos para modificar los oligomeros beta-amiloides usando compuestos no peptidicos.
CO2022005113A2 (es) Métodos de tratamiento para modificar la hemodinámica
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
MX2022000143A (es) Metodos novedosos.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
JOP20220042A1 (ar) طرق لعلاج فرط فينيل ألانين الدم
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
MX2021014526A (es) Metodos no terapeuticos para mantener un peso corporal saludable o perder peso corporal.
MX2021009862A (es) Metodos para obtener celulas de musculo liso inducidas.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.